Candidiasis, chronic mucocutaneous = إلتهابات الحمضيات المزمنة في الأنسجة الجلدية واللسان والأنف واللثة والأذن
Candidiasis Chronic Mucocutaneous
Candidiasis

EPIDEMIOLOGY

Several clinical sub-types have been defined. They have varied clinical manifestations, variable immunodeficiency, and different forms of genetic inheritance. Patients with chronic mucocutaneous candidiasis (CMC) may have childhood or mature onset, familial, or sporadic occurrence, and CMC may be present with or without endocrinopathy. Patients with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED or autoimmune polyendocrine syndrome or APS, type 1) often have affected siblings. APECED and other familial forms of CMC are autosomal recessive. Autosomal dominant inheritance is seen in patients with associated keratitis.

CHRONIC MUCOCUTANEOUS CANDIDIASIS AT AGLANCE
A heterogeneous group of disorders with altered immune responses selective to candida

- Recurrent, progressive candidal infections of the skin, nails, and mucous membranes

- May be associated with the later development of endocrinopathy [autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED)]

ETIOLOGY AND PATHOGENESIS

The clinical features of CMC may be seen in a variety of immunologic disorders, all characterized by ineffective defense mechanisms against Candida. In general, the patients with greater severity and an earlier onset of cutaneous candidal infections have more severe immunologic alterations. CMC patients have shown general dysregulation of interleukin 12 (IL-12), IL-6, and interferon-γ (IFN-γ) production, resulting in an inability to mount a cell-mediated response to clear candidal organisms. Chronic infections result in production of high levels of inflammatory cytokines (IL-6) followed by anti-inflammatory cytokines (IL-10) that further reduce the production of T helper 1 (Th1)-inducing cytokines via a positive feedback loop.

Humoral immunity appears normal in most patients and 25 percent to 35 percent of patients with CMC have no demonstrable immunologic defects. Many patients with CMC have
associated APECED syndrome, owing to mutations in the autoimmune regulator (AIRE) gene which maps to 21q22.3 and encodes a DNA transcription factor. Mice that are deficient in AIRE do not delete organ-specific T cells in the thymus, thus promoting the development of autoimmune disease.

The reason for susceptibility to mucocutaneous candidal infections is unclear. APECED must be distinguished from immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome, an X-linked recessive disorder in which the abnormal development of regulatory T cells results from mutations in the FOXP3 gene. Patients with IPEX syndrome show psoriasiform dermatitis, nail dystrophy, autoimmune endocrinopathies (overlapping with those seen in APECED syndrome), and autoimmune skin conditions such as alopecia universalis.

## Classification of Patients with Chronic Mucocutaneous Candidiasis

<table>
<thead>
<tr>
<th>CMC TYPE</th>
<th>INHERITANCE/GENE DEFECT</th>
<th>ONSET</th>
<th>CLINICAL FEATURES</th>
<th>ASSOCIATED DISORDERS</th>
</tr>
</thead>
</table>
NON-CANDIDAL INFECTIONS

Chronic oral candidiasis

No known genetic defect.

Middle-aged or elderly women.

Candidiasis of tongue and buccal mucosa. No esophageal, skin, or nail involvement.

\[ \text{Fe}^{2+} \text{ deficiency} \]

No

Familial chronic mucocutaneous candidiasis

Autosomal recessive and autosomal dominant. Males and females are equally affected.

Early childhood, often before age 2 yr.

Oral candidiasis. Limited skin and nail involvement.
No endocrinopathies

Yes

Autoimmune polyendocrinopathy-candidiasis-ecto-dermal dystrophy syndrome

Autosomal recessive.
Mutations in the \textit{AIRE} (autoimmune regulator) gene on 21q22.3. More common in the Finnish population, Iranian Jews, and Sardinians. Rarely, dominant form with AIRE mutations or mapped to chromosome 2p.

Candidial infections before age 5 yr.
Endocrine abnormalities between 10 and 15 yr of age.

Oral and diaper area candidiasis more often than skin and nail involvement. Endocrinopathies and autoimmune disorders.

Most common endocrinopathies:

Yes

Hypoparathyroidism
Hypoadrenalism

Other associated disorders:

Thyroid disease
Primary hypogonadism

Hepatitis
Malabsorption

Pernicious anemia
Alopecia areata

Vitiligo
Ectodermal manifestations:

Dental enamel hypoplasia
Pitted nail dystrophy

Keratoconjunctivitis
CMC with thymoma

No known genetic basis.

Adult onset.

Mucous membrane and cutaneous candidiasis.

Malignant/benign thymomas
Aplastic anemia
Myasthenia gravis
Hypogammaglobulinemia

No

Chronic localized candidiasis (candida granuloma)

No known genetic basis.
Males and females are equally affected.
Early childhood, often before age 5 yr.

Thick, adherent candidal crusts on the scalp and face. Oral candidiasis.

None

Yes

CMC with keratitis

Autosomal dominant.

Early childhood.

Candidiasis of the oral cavity, diaper area.

Keratoconjunctivitis
Alopecia
Endocrine abnormalities

Yes
CMC = chronic mucocutaneous candidiasis.

Chronic candidal infections have been described in patients with DiGeorge, hyper-IgE, severe combined immunodeficiency, and other conditions such as the DiGeorge syndrome, hyper-IgE syndrome, autoimmune neutropenia, and depigmentation and keratitis-ichthyosis-deafness syndromes; multiple carboxylase deficiency; and acrodermatitis enteropathica.

CLINICAL FINDINGS

Patients with CMC have recurrent, progressive infections of the skin, nails, and mucous membranes most commonly due to C. albicans. Depending on the subtype, the clinical presentation ranges from recurrent, recalcitrant thrush to mild erythematous scaling plaques with a few dystrophic nails to severe generalized, crusted granulomatous plaques. The cutaneous plaques occur most commonly in intertriginous areas, periorificial sites, and the scalp, but they may be generalized. The nails are thickened, brittle, and discolored, and the paronychial areas are often erythematous, swollen, and tender. Scalp infections may lead to scarring and alopecia. Although the oral mucosa is the most frequent site of mucosal alteration, esophageal, genital, and laryngeal mucosae may be affected. Strictures may be formed by candidal infection at these mucosal sites. Scrapings and cultures from cutaneous or mucosal lesions demonstrate candidal organisms.
Patients with CMC rarely develop systemic candidiasis, but 50 percent may develop recurrent or severe infections due to other organisms. In one study, 81 percent of patients with early-onset CMC also had infections with bacteria, fungi, and parasites, including bacterial septicemia. Concomitant dermatophyte infections may occur.

In patients with APECED, the candidal infections tend to begin by 5 years of age, although the endocrinologic dysfunction may not be apparent until 12 to 13 years of age. The most commonly associated endocrinopathies are hypoparathyroidism (88 percent) and hypoadrenocorticism (60 percent). One-third of patients have candidiasis, hypoparathyroidism, and defective adrenal function. Other associated endocrinopathies or autoimmune disorders include gonadal insufficiency (45 percent), alopecia areata (20 percent), pernicious anemia (16 percent), thyroid abnormalities (12 percent), chronic active hepatitis or juvenile cirrhosis (9 percent), vitiligo, diabetes mellitus, and hypopituitarism. Chronic diarrhea and malabsorption have been reported in 25 percent of patients and usually are associated with hypoparathyroidism. Some affected patients also have pulmonary fibrosis, dental enamel hypoplasia, and keratoconjunctivitis. The “ectodermal dysplasia” features are likely to be secondary to the candidal infections or autoimmunity. Patients with APECED often have autoimmune antibodies, including antithyroglobulin, antimicrosomal antibodies, antiadrenal and antimelanocyte antibodies, and rheumatoid factor. Autoantibodies also have been found in patients with CMC who do not have clinical endocrinologic disease.

PROGNOSIS, CLINICAL COURSE, AND TREATMENT

Candidal lesions in patients with CMC generally respond to systemically administered azole antifungal agents (itraconazole, fluconazole) or terbinafine. Ketoconazole is no longer used because of the risk of hepatitis. Patients who are resistant usually respond to amphotericin B with or without flucytosine. Cutaneous granulomas often are less responsive despite clearance of infection. Recurrences are common, and the antifungal agents must be used intermittently. The drugs have no effect on the abnormal cell-mediated immunity. All patients with CMC should have an annual endocrine evaluation and patients with documented endocrinopathy or a family
history of APECED should be monitored more closely. Patients who have a history of infections other than candidal should have further